<code id='5BF3F800AD'></code><style id='5BF3F800AD'></style>
    • <acronym id='5BF3F800AD'></acronym>
      <center id='5BF3F800AD'><center id='5BF3F800AD'><tfoot id='5BF3F800AD'></tfoot></center><abbr id='5BF3F800AD'><dir id='5BF3F800AD'><tfoot id='5BF3F800AD'></tfoot><noframes id='5BF3F800AD'>

    • <optgroup id='5BF3F800AD'><strike id='5BF3F800AD'><sup id='5BF3F800AD'></sup></strike><code id='5BF3F800AD'></code></optgroup>
        1. <b id='5BF3F800AD'><label id='5BF3F800AD'><select id='5BF3F800AD'><dt id='5BF3F800AD'><span id='5BF3F800AD'></span></dt></select></label></b><u id='5BF3F800AD'></u>
          <i id='5BF3F800AD'><strike id='5BF3F800AD'><tt id='5BF3F800AD'><pre id='5BF3F800AD'></pre></tt></strike></i>

          fashion

          fashion

          author:explore    Page View:1
          Eli Lilly headquarters
          Kristoffer Tripplaar/AP

          Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

          It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

          advertisement

          At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Men with early prostate cancer can safely opt out of treatment
          Men with early prostate cancer can safely opt out of treatment

          AnMRIscanoftheprostate.MichaelOhliger/UCSFMendiagnosedwithearlyprostatecancercansafelychooseactivemo

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

          DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne